Oragenics Inc. (NYSE American: OGEN) announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion) are now active and enrolling participants. The activation of Royal Adelaide Hospital completed the site initiation, following earlier activations at other locations. The company reported that no serious adverse events have been observed in dosed participants to date, and it continues to target a Phase IIa data readout in the fourth quarter of 2026.
ONP-002 is a potential first-in-class treatment for concussion, delivered via Oragenics' proprietary intranasal delivery technology. The ongoing Phase IIa trial aims to evaluate safety and efficacy in patients with mild traumatic brain injury. The company's intranasal platform holds promise for multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
In parallel, Oragenics submitted a Type B meeting request to the U.S. Food and Drug Administration on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002. The company stated that the meeting supports its goal of submitting an Investigational New Drug application in the fourth quarter of 2026. This step is crucial for advancing the therapy toward potential U.S. trials, with Phase 2b studies planned to follow the Australian program.
The activation of all Australian sites and the FDA engagement underscore Oragenics' commitment to addressing the significant unmet medical need in concussion treatment. Concussion affects millions annually, and currently, no FDA-approved therapies exist specifically for mild traumatic brain injury. ONP-002's intranasal delivery could offer rapid, targeted brain uptake, potentially improving outcomes for patients.
For more details, the full press release is available at https://ibn.fm/Yye2E. Additional updates on Oragenics can be found in the company's newsroom at https://ibn.fm/OGEN.
